The May 2020 issue of Pharmafocus is available to read free online now!

pharmafile | April 28, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus, pharma 

The latest monthly edition of Pharmafocus, the May 2020 issue, is available to read for free online now!

COVID-19 continues to dominate the news cycle as we all try to maintain business as usual under the shadow of the pandemic. Just about every area of society and business has been hit and Life Sciences is no exception; the impact of the virus has been felt in every corner of the industry and our monthly issues aim to cut through the confusion to shed a light on that impact.

The world needs an effective therapy for COVID-19, and the industry is locked in a race to make this a reality. You can find the latest news on the most promising candidates in the race, from the chequered tale of the Trump-touted hydroxychloroquine to Europe’s first vaccine to enter human trials.

One of our feature pieces in this issue also explores the impact of the virus on the industry’s R&D capacity, the science behind the most promising therapies, and why managing our expectations about the availability of an effective treatment may be key at this early stage.

Our second feature this month investigates how digital therapeutics are changing the face of treatment, and in our Insider Interview we also speak to Dr LaRee Tracey, a lecturer at San Diego State University and Director of Biostatistics at PHASTAR who discusses how her work using data modelling to predict the spread of the 2014 West African Ebola crisis can shed a light on how we approach this latest outbreak.

Elsewhere in the issue, we also dive into the impact that COVID-19 is having on global vaccination programmes, and why social distancing may be needed “indefinitely” until a vaccine for the virus can be produced.

Check out the latest issue for free online now!

Related Content

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content